StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research note released on Saturday morning. The firm issued a sell rating on the stock.
Trinity Biotech Stock Down 6.1 %
Shares of TRIB stock opened at $0.66 on Friday. The business has a fifty day simple moving average of $0.79 and a 200 day simple moving average of $1.12. The company has a market cap of $12.00 million, a P/E ratio of -0.29 and a beta of 1.20. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55.
Institutional Investors Weigh In On Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its stake in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. 78.97% of the stock is currently owned by institutional investors.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Read More
- Five stocks we like better than Trinity Biotech
- Canadian Penny Stocks: Can They Make You Rich?
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- How to Read Stock Charts for Beginners
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
